04:22 AM EDT, 06/26/2026 (MT Newswires) -- Nuvation Bio (NUVB) has priced its underwritten offering of $250 million of 0.75% convertible senior notes due in 2032, the oncology treatment company announced late Thursday.
Nuvation Bio (NUVB) has also extended to the underwriters an option, or greenshoe, to purchase an additional $37.5 million of the notes.
Nuvation Bio (NUVB) expects net proceeds from the offering will be $241.2 million, or $277.6 million if the greenshoe is exercised, after deducting related expenses.
The notes are convertible into Nuvation Bio (NUVB) shares at 127.5 shares per $1,000 principal amount of notes, or $7.84 a share, which represents a conversion premium of 35.0% to the closing price of the company's shares on the NYSE on Thursday.
Initially, Nuvation Bio (NUVB) had announced the size of the convertible note offering was to be $200 million.
Nuvation Bio (NUVB) expects to use net offering proceeds to repay in full its senior secured loan agreement, and for general corporate purposes.
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.